SHISA2

Across TCGA pan-cancer cohorts, SHISA2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SHISA2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SHISA2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SHISA2 is over-expressed in tumor, although a few such as CCRCC and LSCC show the opposite, repressed pattern.

HNSC, PDAC, and CCRCC are the cancer types where SHISA2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SHISA2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.050	<.001	8	view →
PDAC	All	II,III,IV	+1.451	<.001	6	view →
CCRCC	All	All	−0.996	<.001	4	view →
LSCC	Female	III,IV	−1.350	<.001	3	view →
LUAD	Female	All	−0.537	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SHISA2–HNSC

Open the HNSC breakdown →